EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Use of Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Treatment of Lung Cancer

Serap Özkaya Gül iD, Esra Aydemir iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26104546 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Serap Özkaya Gül und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Faculty of Science, Akdeniz University, Antalya TR-07058, Turkey. Hauptthemen laut MEDLINE: Lung Neoplasms, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is among the most common malignancies globally, is frequently associated with a poor prognosis, and is the second leading cause of cancer-related mortality in both genders. Resistance to treatment, heterogeneity, and invasiveness make lung cancer one of the most challenging tumors to combat. Drug repurposing is considered an advantageous strategy for expediting and economizing drug discovery, as it involves rebranding an existing drug for a new therapeutic use. Since depression is a prevalent psychiatric illness among individuals diagnosed with lung cancer, various selective serotonin reuptake inhibitors (SSRIs) used for the treatment of depression were examined for their possible use in lung cancer treatment as repurposed drugs. Herein, we evaluated the efficacy of SSRIs, both alone and in combination with various anticancer agents, in the treatment of lung cancer along with their mechanisms of action. The innovative approach of repurposing SSRIs offers hope by simplifying the drug discovery process and potentially revealing new therapeutic options for lung cancer. Exploring SSRIs’ effects on lung cancer treatment may unlock unexpected avenues for combating this aggressive disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSelective Serotonin Reuptake InhibitorsAntidepressive AgentsAntineoplastic AgentsHumansDrug RepositioningAnimalsDepression

Stichwörter der Autor:innen

SSRIanticancerantidepressantcancercytotoxicitydrug repurposing

Substanzen

Selective Serotonin Reuptake InhibitorsAntidepressive AgentsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biology, Faculty of Science, Akdeniz University, Antalya TR-07058, Turkey.

ORCID-Profile: Serap Özkaya Gül, Esra Aydemir

Zitieren

APA

Özkaya Gül, S., & Aydemir, E. (2025). The Use of Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Treatment of Lung Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104546

Vancouver

Özkaya Gül S, Aydemir E. The Use of Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Treatment of Lung Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104546

BibTeX
@article{zkayaGl2025,
  author = {Özkaya Gül, Serap and Aydemir, Esra},
  title = {The Use of Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Treatment of Lung Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26104546}
}
Kostenlos starten →